CYTK
What one share of Cytokinetics, Incorporated holds
Pharmaceutical Preparations
We are a biopharmaceutical company focused on discovering, developing and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.
Cytokinetics, Incorporated’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.54 |
|---|---|
| Profit | −$7.18 |
| Capex (buildings and equipment) | $0.20 |
| Free cash flow | −$4.67 |
| Cash and investments | $1.84 |
| Debt | $1.98 |
| Book value | −$1.25 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | $8.44 | $2.54 | $0.06 | $0.81 | — | $10.60 |
| 2010 | $0.24 | −$4.61 | $0.05 | −$4.24 | — | $6.32 |
| 2011 | $0.34 | −$4.30 | $0.04 | −$3.90 | — | $3.86 |
| 2012 | $0.42 | −$2.30 | $0.01 | −$1.85 | — | $2.95 |
| 2013 | $1.12 | −$1.24 | $0.02 | −$0.30 | — | $1.77 |
| 2014 | $1.31 | −$0.41 | $0.03 | −$1.29 | — | $2.38 |
| 2015 | $0.74 | −$0.97 | $0.01 | $0.11 | — | $1.73 |
| 2016 | $2.50 | $0.39 | $0.04 | $0.83 | — | $2.32 |
| 2017 | $0.27 | −$2.59 | $0.06 | −$2.12 | — | $2.04 |
| 2018 | $0.58 | −$1.95 | $0.02 | −$1.88 | — | $0.47 |
| 2019 | $0.47 | −$2.11 | $0.05 | −$1.62 | — | −$0.18 |
| 2020 | $0.87 | −$1.97 | $0.17 | −$0.03 | — | $1.60 |
| 2021 | $0.92 | −$2.80 | $0.64 | −$2.49 | — | $2.88 |
| 2022 | $1.05 | −$4.33 | $0.13 | −$3.46 | — | −$1.14 |
| 2023 | $0.08 | −$5.45 | $0.01 | −$4.31 | — | −$3.80 |
| 2024 | $0.17 | −$5.26 | $0.03 | −$3.57 | — | −$1.15 |
| 2025 | $0.73 | −$6.54 | $0.21 | −$4.45 | — | −$5.37 |